Five quality indicators from The National Cancer Data Base's Cancer Program Practice Profile Report are included below. Three indicators are for breast cancer and two for colon cancer. Also included for each measure is the Commission on Cancer's expected performance rate for individual hospitals. Elmhurst Memorial Healthcare exceeded the expected performance rates for each of these measures.

To learn more about the National Cancer Data Base, please click here.

Colon Cancers

The following two colon cancer quality-focused measures have been endorsed by the National Quality Forum (NQF). With submission of EMHC-specific data to the National Cancer Data Base (NCDB) we are able to compare our compliance rate of these accountability or quality improvement measures against state and national rates. These measures emphasize not only the quality of patient care but also the importance of accurate and complete documentation.

Comparison data below is for colon cancer cases diagnosed in calendar year 2010.

Adjuvant chemotherapy – colon cancer

Adjuvant chemotherapy is considered or administered within 4 months (120 days) of diagnosis for patients under the age of 80 with AJCC Stage III (lymph node positive) colon cancer.

12 Regional Lymph Nodes – colon cancer

At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer.

Source: American College of Surgeons-Commission on Cancer (ACoS-CoC), National Cancer Data Base (NCDB), Cancer Program Practice Profile Report (CP3R)-October 2012
EMHC: Elmhurst Memorial Healthcare
IL: All ACoS-CoC Accredited Cancer Programs in State of Illinois
CCCP: All ACoS-CoC Accredited Comprehensive Community Cancer Programs (EMHC is a CCCP program)

---

Breast Cancer

The following three breast cancer quality-focused measures have been endorsed by the National Quality Forum (NQF). With submission of EMHC-specific data to the National Cancer Data Base (NCDB), we are able to compare our compliance rate of these accountability measures against state and national rates. These measures emphasize not only the quality of patient care but also the importance of accurate and complete documentation.

Comparison data below is for breast cancer cases diagnosed in calendar year 2010.

Breast Conservation Surgery/Radiation Therapy

Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer.

Combination Chemotherapy

Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1c N0 M0, or Stage II or III ERA and PRA negative breast cancer.

Hormone Therapy

Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1c N0 M0, or Stage II or III ERA and/or PRA positive breast cancer.

Source: American College of Surgeons-Commission on Cancer (ACoS-CoC), National Cancer Data Base (NCDB), Cancer Program Practice Profile Report (CP3R)-October 2012
EMHC: Elmhurst Memorial Healthcare
IL: All ACoS-CoC Accredited Cancer Programs in State of Illinois
CCCP: All ACoS-CoC Accredited Comprehensive Community Cancer Programs (EMHC is a CCCP program)